$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
奥拉帕尼治疗复发的BRCA胚系突变的乳腺癌患者
2025-10-19 11:44:20
Check Details
奥拉帕利获批治疗胰腺癌
2025-10-19 11:44:20
Check Details
帕博西林乳腺癌治疗新选择
2025-10-19 11:44:20
Check Details
mTOR拟制剂依维莫司带来治疗激素受体阳性晚期乳腺癌的新突破
2025-10-19 11:44:20
Check Details
内分泌治疗联合依维莫司可治疗芳香化酶失败后的晚期乳腺癌
2025-10-19 11:44:20
Check Details
尼拉帕尼治疗存在BRCA突变的乳腺癌
2025-10-19 11:44:20
Check Details
帕博西林联合来曲唑治疗晚期乳腺癌
2025-10-19 11:44:20
Check Details
依维莫司联合依西美坦治疗乳腺癌
2025-10-19 11:44:20
Check Details
帕博西尼联合来曲唑治疗HER 2-乳腺癌患者
2025-10-19 11:44:20
Check Details
帕博西尼+来曲唑延长乳腺癌患者的无进展生存期
2025-10-19 11:44:20
Check Details
帕博西尼治疗乳腺癌优于来曲唑
2025-10-19 11:44:20
Check Details
转移性乳腺癌的一线用药帕博西林联合芳香化酶抑制剂
2025-10-19 11:44:20
Check Details
1
2
...
7732
7733
7734
7735
7736
7737
7738
...
10233
10234
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Finerenone (Kerendia) for Diabetic CKD and HF with LVEF≥40%: Albuminuria, Dosing, Hyperkalemia
2
Baxdrostat (Baxfendy) for Hypertension: Aldosterone Synthase Inhibition, Dosing, and Discontinuation Rules
3
Pixclara (Floretyrosine F-18/18F-FET) Glioma PET: Distinguishing Recurrence from Treatment-Related Change
4
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
5
Bexlutry (Lu-177 Dotatate) for SSTR-Positive GEP-NETs: PRRT Dosing and Safety Monitoring
6
Etrasimod for Ulcerative Colitis: 2mg Once Daily, Onset Timeline, and Safety Monitoring
7
Hibsago (Bepirovirsen) Japan Approval: CHB Functional Cure and B-Well Data Essentials
8
FDA Approves Isembyld (apitegromab-mstn), the World’s First Skeletal Muscle-Targeted Therapy for SMA
9
Post-Enzalutamide mCRPC: HRR/PARP, PSMA Radioligand, and Chemotherapy Sequencing
10
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
11
Acalabrutinib in CLL/SLL Survival Expectation: ELEVATE-TN and ASCEND Long-Term PFS, OS
12
Bosutinib for CML: Time to Response, BCR-ABL Monitoring, and Molecular Remission